Pharmaceutical

Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy

Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for patients with dry eye disease (DED) in Europe.

Oct 4, 2024 - 04:00
Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy
Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for patients with dry eye disease (DED) in Europe.
Read the original article

Tags:

Previous Article

ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer

Next Article

Gilead signs agreements to facilitate access to HIV prevention drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biogen says it will cut costs by $700 million, slash 1,000 jobs

STAT+: Biogen says it will cut costs by $700 million, s...

Jul 26, 2023

STAT+: NEJM aims to hold AI to account with new publication

STAT+: NEJM aims to hold AI to account with new publica...

Dec 11, 2023

Moderna to set up new mRNA manufacturing facility in Kenya

Moderna to set up new mRNA manufacturing facility in Kenya

Mar 31, 2023